Acetyl-L-carnitine as a possible therapy for Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 2, Issue 5, 2002, Pages 647-654

  Pettegrew, Jay W ^a   McClure, Richard J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alzheimer's disease; High energy phosphate; Mitochondria; Phospholipid metabolism

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; LEVACECARNINE; MEMBRANE PHOSPHOLIPID; TACRINE;

ADJUVANT THERAPY; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; PHOSPHOLIPID METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; REVIEW;

EID: 0036047955     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.2.5.647     Document Type: Review

References (78)

1. Acetyl-L-carnitine physical-chemical, metabolic and therapeutic properties: Relevance for its mode of action in Alzheimer's disease and geriatric depression
2. Molecular insights into Alzheimer's disease
3. Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia
4. Three-dimensional analysis of the relationship between synaptic pathology and neuropil threads in Alzheimer's disease
5. Molecular insights into neurodevelopmental and neurodegenerative disease
6. Phospholipid metabolism and cell signalling in eucaryotes
7. Elevated phosphocholine and phosphatidyl choline following rat entorhinal cortex lesions
8. Alterations of selected enzymes of phospholipid metabolism in Alzheimer's disease brain tissue as compared to non-Alzheimer's disease controls
9. Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease
10. Alterations of cerebral metabolism in probable Alzheimer's disease: A preliminary study
11. 31P Nuclear magnetic resonance study of the brain in Alzheimer's disease
12. Evidence for a membrane defect in Alzheimer's disease brain
13. 31P MRS of PCA extracts of postmortem Alzheimer's disease brain
14. Aggregation of β-amyloid peptide is promoted by membrane phospholipid membrane phospholipid metabolites elevated in Alzheimer's disease brain
15. Magnetic resonance spectroscopic changes in Alzheimer's disease
16. Structural changes in Alzheimer's disease brain membrane mediated by alteration in cholesterol
17. Apolipoprotein E. Cholesterol transport protein with expanding role in cell biology
18. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
19. Brain membrane phospholipid alterations in Alzheimer's disease
20. Functional rafts in cell membranes
21. Caveolae, DIGs and the dynamics of sphingolipid-cholesterol microdomains
22. Sphingomyelin hydrolysis and regulation of the expression of the gene for cytochrome P450
23. High plasmalogen and arachidonic add content of canine myocardial sarcolemma: A fast atom bombardment mass spectroscopic and gas chromatography-mass spectroscopic characterization
24. Studies on ether phospholipids II. Comparative composition of various tissues from human, rat and guinea-pig
25. Is the high propensity of ethanolamine plasmalogens to form non-lamellar lipid structures manifested in the properties of biomembranes?
26. Plasmenylethanolamine facilitates rapid membrane fusion: A stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane fusion
27. Membrane phospholipid alterations in Alzheimer's disease: Deficiency of ethanolamine plasmalogens
28. Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting
29. 3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth
30. Lipid modulation of cell function
31. The cleavage of plasmenylethanolamine by phospholipase A2 appears to be mediated by the low affinity binding site of the TxA2/PGH2 receptor in U46619-stimulated human platelets
32. Identification of plasmalogen as the major phospholipid constituent of cardiac sarcoplasmic reticulum
33. Ether lipids in biomembranes
34. Oxygen-dependent cleavage of the vinyl-ether linkage of plasmologens. 1. Cleavage by rat-brain supernatant
35. Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro
36. Plasmalogen phospholipids as potential protectors against lipid peroxidation of low density lipoproteins
37. Plasmalogens, phospholipases A2 and signal transduction
38. Metabolism and function of myo-inositol and inositol phospholipids
39. Metabolic alterations in postmortem Alzheimer's disease brain are exaggerated by Apo-E4
40. Chronic myo-inositol increases rat brain phosphatidylethanolamine plasmalogen
41. The biosynthesis and functional role of cardiolipin
42. Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain
43. The role of the phosphoinositide signaling system in the pathgenesis of sporadic Alzheimer's disease: A hypothesis
44. Functional binding of cardiolipin to cytochrome c oxidase
45. Brain cytochrome oxidase in Alzheimer's disease
46. Interaction of amyloid beta-protein with anionic phospholipids: Possible involvement of Lys28 and C-terminus aliphatic amino acids
47. Changes in brain energy and phospholipid metabolism during development and aging in the Fischer 344 rat
48. The synthesis and transport of lipids for axonal growth and nerve regeneration
49. Kinesin and dynein superfamily proteins and the mechanism of organelle transport
50. Long-term acetyl-L-camitine treatment in Alzheimer's disease
51. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease
52. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease
53. Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: A re-analysis of a double-blind, placebo-controlled study using the trilinear approach
54. Use of acetylcholinesterase inhibitors in Alzheimer's disease
55. Donepezil in the treatment of patients with Alzheimer's disease
56. Efficacy of donepezil in Alzheimer's disease: Fact or artifact?
57. Commentary: Another piece of the Alzheimer's jigsaw
58. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease
59. Effect of L-carnitine and acetyl-L-carnitine on the human erythrocyte membrane stability and deformability
60. Synaptic pathology of Alzheimer's disease
61. Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration
62. Synapse alterations in the hippocampalentorhinal formation in Alzheimer's disease with and without Lewy body disease
63. Reduced Oglycosylated clathrin assembly protein AP180: Implication for synaptic vesicle recycling dysfunction in Alzheimer's disease
64. Neurochemical dissection of synaptic pathology in Alzheimer's disease
65. Biological markers in Alzheimer's disease
66. Anatomic and functional brain imaging in Alzheilmer's disease
67. Brain energy metabolizing enzymes in Alzheimer's disease: Alpha-ketoglutarate dehydrogenase complex and cytochrome oxidase
68. Action of Lacetylcamitine on different cerebral mitochondrial populations from cerebral cortex
69. Brain energy metabolism, cognitive function and downregulated oxidative phosphorylation in Alzheimer's disease
70. Evidence for physiological downregulation of brain oxidative phosphorylation in Alzheimer's disease
71. Altered glucose metabolism in microvessels from patients with Alzheimer's disease
72. Experimental therapeutics
73. The action of acetyl-L-carnitine on the neurotoxicity evoked by amyiloid fragments and peroxide on on primary rat cortical neurones
74. Effect of acetyl-L-carnitine on forebrain cholinergic neurons of developing rats
75. Stimulation of nerve growth factor receptors in PC12 by acetyl-L-canitine
76. Comparison of the conformation of amyloid beta(1-28) peptide fragment with its Lys28 N-acetyl derivative
77. 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: Preliminary results